WASHINGTON — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk aimed at expanding access and reducing prices for their popular obesity treatments, Zepbound and Wegovy. These medications, classified as GLP-1 receptor agonists, have gained tremendous popularity in recent years, but high costs—approximately $500 monthly for higher doses—have limited patient access. The new initiative will extend Medicare coverage for these medications starting next year while providing some price reductions for those without insurance, with initial doses of new pill versions potentially priced at $149 a month pending approval.
In response to worsening cost-of-living concerns among voters, this latest announcement marks an effort by the Trump administration to rein in soaring drug prices. Drugmakers Pfizer and AstraZeneca recently committed to lowering prescription costs following an executive order mandating price reductions. Despite the price drops, uncertainty remains regarding the actual financial relief consumers will experience due to variations in treatment competition and insurance coverage.
The obesity drugs function by influencing hormones that regulate appetite, leading to significant weight loss—often between 15% to 22% of body weight in trial participants. Despite their effectiveness, many Americans remain unable to afford these treatments due to prohibitive costs and lack of adequate healthcare coverage.
This push to make GLP-1 drugs more accessible comes as the White House seeks to demonstrate Trump's awareness of the rising costs faced by Americans across various sectors, including housing, healthcare, and food. Recent electoral losses among Republican candidates in key states reflect voters’ dissatisfaction with economic conditions. Administration officials highlighted that beginning next year, qualifying Medicare patients could see standard copays of $50 for these medications as the government introduces a TrumpRx program to facilitate direct purchasing from manufacturers.
Healthcare professionals have expressed hope that these changes will alleviate financial barriers for patients reliant on obesity treatments. Nonetheless, skepticism remains about the sustained affordability and implementation of these proposed reforms, particularly among doctors treating obesity, who emphasize the need for tangible solutions to effectively manage costs and improve patient access.
In response to worsening cost-of-living concerns among voters, this latest announcement marks an effort by the Trump administration to rein in soaring drug prices. Drugmakers Pfizer and AstraZeneca recently committed to lowering prescription costs following an executive order mandating price reductions. Despite the price drops, uncertainty remains regarding the actual financial relief consumers will experience due to variations in treatment competition and insurance coverage.
The obesity drugs function by influencing hormones that regulate appetite, leading to significant weight loss—often between 15% to 22% of body weight in trial participants. Despite their effectiveness, many Americans remain unable to afford these treatments due to prohibitive costs and lack of adequate healthcare coverage.
This push to make GLP-1 drugs more accessible comes as the White House seeks to demonstrate Trump's awareness of the rising costs faced by Americans across various sectors, including housing, healthcare, and food. Recent electoral losses among Republican candidates in key states reflect voters’ dissatisfaction with economic conditions. Administration officials highlighted that beginning next year, qualifying Medicare patients could see standard copays of $50 for these medications as the government introduces a TrumpRx program to facilitate direct purchasing from manufacturers.
Healthcare professionals have expressed hope that these changes will alleviate financial barriers for patients reliant on obesity treatments. Nonetheless, skepticism remains about the sustained affordability and implementation of these proposed reforms, particularly among doctors treating obesity, who emphasize the need for tangible solutions to effectively manage costs and improve patient access.
